HC Wainwright Lifts Earnings Estimates for Aktis Oncology

Aktis Oncology (NASDAQ:AKTS) – Analysts at HC Wainwright upped their Q2 2026 EPS estimates for Aktis Oncology in a research note issued on Tuesday, June 2nd. HC Wainwright analyst R. Burns now expects that the technology company will post earnings of ($0.36) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.64) EPS, Q1 2027 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.20) EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, May 26th. William Blair initiated coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.50.

Aktis Oncology Price Performance

Shares of NASDAQ AKTS opened at $19.37 on Thursday. The firm’s 50 day simple moving average is $18.92. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $29.16.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million for the quarter.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.